SCHEMBL5237304

SCHEMBL5237304

CCCCOc1c(CN2C(=O)c3ccccc3C2=O)n(Cc2ccccc2)c(=O)c2cc(Cl)c(Cl)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.43
PTK2B Q14289 1/20 0.43
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
RECQL P46063 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39
CASP3 P42574 2/20 0.39
PDE4A P27815 2/20 0.39
PDE4B Q07343 2/20 0.39
PDE4C Q08493 2/20 0.39
PDE4D Q08499 2/20 0.39
TLR7 Q9NYK1 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5234899 0.89 NPSR1 (0.45) TSHRPTK2BCASP3NPSR1KMT2A
SCHEMBL5237977 0.88 TSHR (0.41) TSHRPTK2BALDH1A1CASP3NPSR1
SCHEMBL5239302 0.88 TSHR (0.39) TSHRPTK2BALDH1A1HPGDCASP3
SCHEMBL5237718 0.88 TSHR (0.42) TSHRPTK2BKDM4EALDH1A1HPGD
SCHEMBL6109221 0.87 TSHR (0.46) TSHRPTK2BKDM4EALDH1A1RECQL
SCHEMBL5266554 0.86 TSHR (0.40) TSHRPTK2BHPGDGABRA1GABRG2
SCHEMBL5232665 0.86 TSHR (0.38) TSHRPTK2BCASP3NPSR1
SCHEMBL5276978 0.86 TSHR (0.40) TSHRPTK2BALDH1A1HPGDCASP3
SCHEMBL5240609 0.86 PDE4A (0.42) TSHRKDM4EALDH1A1PDE4APDE4B
SCHEMBL5232612 0.86 NPSR1 (0.44) TSHRPTK2BNPSR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355886-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-07-11 EP disclosed
US-7034039-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-25 US disclosed
US-20040082607-A1 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082607-A1 Fused heterocyclic compounds DPP7, DPP4, METAP1 TSHR 2475/4885PTK2B 3599/4885KDM4E 897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.